Vittorio Gebbia

机构：Università degli Studi di Enna Kore, University of Palermo · ORCID：0000-0001-8848-5951

发表论文 454 篇 · 总被引 17341 次 · h-index 53

代表论文

• Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial (2018 · The Lancet Oncology · 被引 89)
• Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials (2018 · Journal of Clinical Oncology · 被引 71)
• Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial (2022 · Journal of Thoracic Oncology · 被引 70)
• A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations (2021 · Translational Lung Cancer Research · 被引 68)
• Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study (2019 · The Breast · 被引 58)
• Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials (2021 · BMC Cancer · 被引 22)